International name - Montelukast (Montelukast). The active ingredient - montelukast sodium.
The pharmacological action of SINGULAIR
In bronchial asthma leykotrienoposredovannye effects trigger mechanism bronchospasm released sputum, reduced patency of the bronchi and increase the number of eosinophils. Montelukast - active compound binds with high selectivity to SysLT1 receptors causes receptor blocking tsisteinilleykotrienovyh in the respiratory tract, the drug is determined by its ability to inhibit bronchoconstriction in people with asthma. Even small doses of 5 mg significantly block the bronchoconstriction caused by LTD4. Following oral administration, the preparation is the adoption of bronchodilation that lasts about two hours.
Thus, as shown by a feedback Singulair can inhibit bronchoconstriction at any stage, both early and late, reducing the response to antigens.
After receiving Singulair is rapidly absorbed by the body. When making a tablet fasted adult, fixed maximum concentration in the blood after 3 hours. Bioavailability is 64% material. The efficacy and safety have been confirmed in clinical trials in the groups that received coated tablets 10 mg, regardless of the meal. About 99% of the drug binds to the plasma protein. Like its counterparts Singulair is extensively metabolised. Studies have shown that the role of metabolites in the therapeutic effect of SINGULAIR minimal.
When taken orally dose singular, isotope-labeled, 86% is set excretion with feces within five days 0 and about 2% in the urine. This fact shows that the metabolites are excreted almost entirely in the bile.
Receiving SINGULAIR in doses of 20-60 times greater than recommended, shows a decrease in plasma theophylline. However, this effect is not observed when a normal dose not exceeding 10 mg per day.
Coated tablets: for adults and children 15 years of age, according to the instructions Singulair can be used as adjuvant treatment of persistent asthma severity different forms, poorly controlled with inhaled corticosteroids or adrenergic agonists, and also for the treatment of seasonal allergic rhinitis origin in patients with bronchial asthma .
Also, as a preventive asthma attack brought on by physical exertion.
Singulair Chewable Tablets:
- are written for children from 2 to 15 years, as an adjunct treatment for persistent asthma of varying severity;
- as an alternative to treatment with low doses of inhaled corticosteroids in mild asthma;
- in case of intolerance inhalers as prevention before exercise for patients with asthma.
Instructions for use Singulair
Coated tablets. Children from 15 years and adults, one tablet (10 mg) per day.
Chewable tablets. Children from 2-15 years old, used only under adult supervision.
Young children from 2 to 5 years of age receive one tablet SINGULAIR (4 mg) once daily - one hour before the evening meal, or after two hours. Children 6 to 14 years receive 1 tablet (5 mg) once in the evening for an hour before eating or two hours after. The need for individual selection of doses available.
Contraindications to the use of the singular
- High sensitivity to the drug.
- Children under 2 years old, in any form.
- Children under 15 years old, film-coated tablets.
- 10 mg tablets are taken only after consulting a doctor.
There are: headache, abdominal pain, excessive bleeding, anaphylaxis, dizziness, hypotension, tachycardia, diarrhea, dyspepsia, dry mouth, vomiting, nausea, insomnia, nightmares, hallucinations, irritability, insomnia, agitation, aggressive behavior, depression tremors, convulsions, rarely - desire for suicide. There are skin manifestations in the form of rash, urticaria, bruising, edema.
Singulair is not relieves asthma attacks, it needs to apply the appropriate drugs. It is also not recommended to move sharply to the inhaled or oral corticosteroids and their analogues in the singular. The therapeutic effect of SINGULAIR on control asthma attack works during the day. Unlike analog, Singulair is taken without reference to food intake. It is recommended not to interrupt the reception is singular even with exacerbations of asthma or transfer a controlled stage. No dose adjustment is required for elderly patients and patients with hepatic or renal insufficiency mild.
Singulair may be in addition to inhaled glucocorticosteroid therapy.
Pregnancy and breast-feeding
There is quite practical feedback on singular, as a means of therapy during pregnancy and lactation, so the appointment must be weighed against the benefit to the mother and the potential harm to the child.
There is no research data on the penetration of SINGULAIR in breast milk, so when applied as necessary to consider the risks and benefits.
Not applicable singular influence on the concentration and the ability to drive, but in some patients, while taking may occur drowsiness and dizziness due to better refrain from managing transport during therapy.
Information on the treatment of overdose is not singular. In most cases of overdose SINGULAIR reviews suggest that there are no side effects were observed. In some cases, the result of an overdose may be abdominal pain, thirst, drowsiness, vomiting, headache, hyperactivity.
The instructions singular no data on possible elimination of the drug by peritoneal dialysis or hemodialysis.
Recommended for Singulair instructions stored only in their original packaging, at a temperature range of +15 and +30 ° C.